FiercePharma6d
Astellas shifts investment focus to later-stage opportunities amid reprioritization
In the last few years, Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry. With multiple programs now nearing proof-of ...
FiercePharma4d
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital ...
pharmaphorum3d
FDA changes its mind on Astellas' geographic atrophy drug
Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...
Yahoo Finance13d
Astellas seeks conditional approval for GA treatment in Japan
Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking conditional approval of avacincaptad pegol intravitreal solution (ACP) to treat ...
MedCity News27d
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part of its growth strategy. Newer products in its drug lineup include a ...
Yahoo Finance7d
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
On Monday, Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev ...
Benzinga.com7d
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Enfortumab vedotin plus pembrolizumab cut the risk of death by 49% vs. chemo, with a median OS of 33.8 months vs. 15.9 months. The combination therapy reduced disease progression or death risk by ...
Business Insider8d
Pfizer and Astellas announce results from phase 3 EV-302 clinical trial
Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and safety of PADCEV, or enfortumab vedotin-ejfv, a Nectin-4 ...
Nasdaq13d
Astellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In Japan
(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP ...
pharmaphorum3d
FDA says no to Astellas' geographic atrophy drug
Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a ...
AD12d
Ongeval met letsel op Industrieweg in Meppel
112 MeldingOp de Industrieweg in Meppel heeft donderdagavond een ongeval plaatsgevonden, waarbij mogelijk één of meerdere personen gewond zijn geraakt. Het ongeval gebeurde ongeveer kwart over ...
RTV Drenthe25d
Verbindingsweg tussen A28 en A32 bij Meppel blijft uren afgesloten na ongelukken
De verbindingsweg tussen de A28 en de A32 bij Meppel is voorlopig afgesloten. Binnen een uur zijn daar twee auto's van de weg geraakt. Rijkswaterstaat heeft de verbindingsweg, die deel uitmaakt ...